Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy

Amir Ajoolabady, Yaguang Bi, David J. McClements, Gregory Y.H. Lip, Des R. Richardson, Russel J. Reiter, Daniel J. Klionsky, Jun Ren

Producción científica: Review articlerevisión exhaustiva

20 Citas (Scopus)

Resumen

Atherosclerosis refers to a unique form of chronic proinflammatory anomaly of the vasculature, presented as rupture-prone or occlusive lesions in arteries. In advanced stages, atherosclerosis leads to the onset and development of multiple cardiovascular diseases with lethal consequences. Inflammatory cytokines in atherosclerotic lesions contribute to the exacerbation of atherosclerosis. Pharmacotherapies targeting dyslipidemia, hypercholesterolemia, and neutralizing inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-17, and IL-12/23) have displayed proven promises although contradictory results. Moreover, adjuvants such as melatonin, a pluripotent agent with proven anti-inflammatory, anti-oxidative and neuroprotective properties, also display potentials in alleviating cytokine secretion in macrophages through mitophagy activation. Here, we share our perspectives on this concept and present melatonin-based therapeutics as a means to modulate mitophagy in macrophages and, thereby, ameliorate atherosclerosis.

Idioma originalEnglish (US)
Número de artículo106072
PublicaciónPharmacological Research
Volumen176
DOI
EstadoPublished - feb 2022

ASJC Scopus subject areas

  • Pharmacology

Huella

Profundice en los temas de investigación de 'Melatonin-based therapeutics for atherosclerotic lesions and beyond: Focusing on macrophage mitophagy'. En conjunto forman una huella única.

Citar esto